Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Experimental confirmation of the C3 tickover hypothesis by studies with an Ab (S77) that inhibits tickover in whole serum.

Lachmann PJ, Lay E, Seilly DJ.

FASEB J. 2018 Jan;32(1):123-129. doi: 10.1096/fj.201700734. Epub 2017 Aug 29.

PMID:
28855277
2.

Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.

Yaseen S, Demopulos G, Dudler T, Yabuki M, Wood CL, Cummings WJ, Tjoelker LW, Fujita T, Sacks S, Garred P, Andrew P, Sim RB, Lachmann PJ, Wallis R, Lynch N, Schwaeble WJ.

FASEB J. 2017 May;31(5):2210-2219. doi: 10.1096/fj.201601306R. Epub 2017 Feb 10.

3.

Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype.

Lachmann PJ, Lay E, Seilly DJ, Buchberger A, Schwaeble W, Khadake J.

Clin Exp Immunol. 2016 Jan;183(1):150-6. doi: 10.1111/cei.12714. Epub 2015 Nov 5.

4.

Traditional passive immune therapy for emerging Ebola infection.

Lachmann PJ.

Emerg Microbes Infect. 2014 Nov;3(11):e81. doi: 10.1038/emi.2014.87. Epub 2014 Nov 19. No abstract available.

5.

Editorial: the urgent need to reform the present system of medicines' regulation.

Lachmann PJ.

Rev Recent Clin Trials. 2015;10(1):2-4. No abstract available.

PMID:
25925887
6.

A more radical solution.

Lachmann PJ.

Rev Recent Clin Trials. 2015;10(1):25-7.

PMID:
25925882
7.

Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle in vitro.

Lay E, Nutland S, Smith JE, Hiles I, Smith RA, Seilly DJ, Buchberger A, Schwaeble W, Lachmann PJ.

Clin Exp Immunol. 2015 Aug;181(2):314-22. doi: 10.1111/cei.12437.

8.

Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection.

Ali YM, Hayat A, Saeed BM, Haleem KS, Alshamrani S, Kenawy HI, Ferreira VP, Saggu G, Buchberger A, Lachmann PJ, Sim RB, Goundis D, Andrew PW, Lynch NJ, Schwaeble WJ.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5301-6. doi: 10.1073/pnas.1401011111. Epub 2014 Mar 24.

9.

Health care: Better drug access for terminal patients.

Brindley DA, Barker RW, Lachmann PJ.

Nature. 2013 Oct 3;502(7469):38. doi: 10.1038/502038c. No abstract available.

PMID:
24091972
10.

The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals.

Lachmann PJ.

QJM. 2012 Dec;105(12):1179-89. doi: 10.1093/qjmed/hcs148. Epub 2012 Aug 20.

11.

The use of antibodies in the prophylaxis and treatment of infections.

Lachmann PJ.

Emerg Microbes Infect. 2012 Aug;1(8):e11. doi: 10.1038/emi.2012.2. Epub 2012 Aug 8. Review.

12.

The grandmother effect.

Lachmann PJ.

Gerontology. 2011;57(4):375-7. doi: 10.1159/000324242. Epub 2011 Mar 29. Review.

13.

Religion--an evolutionary adaptation.

Lachmann PJ.

FASEB J. 2010 May;24(5):1301-7. doi: 10.1096/fj.10-0502ufm. No abstract available.

PMID:
20430796
14.

Preparing serum for functional complement assays.

Lachmann PJ.

J Immunol Methods. 2010 Jan 31;352(1-2):195-7. doi: 10.1016/j.jim.2009.11.003. Epub 2009 Nov 10.

PMID:
19909755
15.

Taking complement to the clinic--has the time finally come?

Lachmann PJ, Smith RA.

Scand J Immunol. 2009 Jun;69(6):471-8. doi: 10.1111/j.1365-3083.2009.02258.x. Review.

16.

The amplification loop of the complement pathways.

Lachmann PJ.

Adv Immunol. 2009;104:115-49. doi: 10.1016/S0065-2776(08)04004-2. Epub 2009 Dec 1.

PMID:
20457117
17.

Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities.

Fernie-King BA, Seilly DJ, Binks MJ, Sriprakash KS, Lachmann PJ.

Microbes Infect. 2007 Mar;9(3):300-7. Epub 2007 Jan 8.

PMID:
17303463
18.

The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus.

Manderson AP, Carlucci F, Lachmann PJ, Lazarus RA, Festenstein RJ, Cook HT, Walport MJ, Botto M.

Arthritis Res Ther. 2006;8(3):R68. Epub 2006 Apr 10.

19.

Inhibition of antimicrobial peptides by group A streptococci: SIC and DRS.

Fernie-King BA, Seilly DJ, Lachmann PJ.

Biochem Soc Trans. 2006 Apr;34(Pt 2):273-5.

PMID:
16545092
20.

Attribution of the various inhibitory actions of the streptococcal inhibitor of complement (SIC) to regions within the molecule.

Binks MJ, Fernie-King BA, Seilly DJ, Lachmann PJ, Sriprakash KS.

J Biol Chem. 2005 May 20;280(20):20120-5. Epub 2005 Mar 15.

21.

Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics.

Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM.

Curr Pharm Des. 2004;10(23):2891-905. Review.

PMID:
15379675
22.
23.

Determination of CD59 protein in normal human serum by enzyme immunoassay, using octyl-glucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex.

Landi AP, Wilson AB, Davies A, Lachmann PJ, Ferriani VP, Seilly DJ, Assis-Pandochi AI.

Immunol Lett. 2003 Dec 15;90(2-3):209-13.

PMID:
14687727
24.

Lupus and desoxyribonuclease.

Lachmann PJ.

Lupus. 2003;12(3):202-6. Review.

PMID:
12708782
25.

Consent and confidentiality--where are the limits? An introduction.

Lachmann PJ.

J Med Ethics. 2003 Feb;29(1):2-3. No abstract available.

26.

Stem cell therapy: medical advance or moral challenge?

Lachmann PJ.

C R Biol. 2002 Oct;325(10):1049-51.

PMID:
12494503
27.

Subversion of the innate immune response by micro-organisms.

Fernie-King B, Seilly DJ, Davies A, Lachmann PJ.

Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii8-12. Review. No abstract available.

29.

Microbial subversion of the immune response.

Lachmann PJ.

Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8461-2. Epub 2002 Jun 19. No abstract available.

30.

The Lloyd Roberts Lecture. Immunopathology: past, present and future.

Lachmann PJ.

Trans Med Soc Lond. 1999-2000;116:18-30. No abstract available.

PMID:
11930787
31.
32.

Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.

Fernie-King BA, Seilly DJ, Willers C, Würzner R, Davies A, Lachmann PJ.

Immunology. 2001 Jul;103(3):390-8.

33.

Interaction between host complement and mosquito-midgut-stage Plasmodium berghei.

Margos G, Navarette S, Butcher G, Davies A, Willers C, Sinden RE, Lachmann PJ.

Infect Immun. 2001 Aug;69(8):5064-71.

35.

Systemic lupus erythematosus, complement deficiency, and apoptosis.

Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ.

Adv Immunol. 2000;76:227-324. Review. No abstract available.

PMID:
11079100
37.

Anti-DNA antibodies in the urine of lupus nephritis patients.

Macanovic M, Hogarth MB, Lachmann PJ.

Nephrol Dial Transplant. 1999 Jun;14(6):1418-24.

PMID:
10383001
38.

Comparison of C1q-receptors on rat microglia and peritoneal macrophages.

Wing MG, Seilly DJ, Nicholas RS, Rahman S, Zajicek J, Lachmann PJ, Compston DA.

J Neuroimmunol. 1999 Feb 1;94(1-2):74-81.

PMID:
10376938
39.

Public health and bioethics.

Lachmann PJ.

J Med Philos. 1998 Jun;23(3):297-302.

PMID:
9736191
40.

Neuronal protection of oligodendrocytes from antibody-independent complement lysis.

Agoropoulou C, Piddlesden SJ, Lachmann PJ, Wing MG.

Neuroreport. 1998 Mar 30;9(5):927-32.

PMID:
9579692
41.

Microbial immunology: a new mechanism for immune subversion.

Lachmann PJ.

Curr Biol. 1998 Jan 29;8(3):R99-R101. Review.

42.

Complement and immunity to viruses.

Lachmann PJ, Davies A.

Immunol Rev. 1997 Oct;159:69-77. Review.

PMID:
9416503
44.

Difficulties in the ascertainment of C9 deficiency: lessons to be drawn from a compound heterozygote C9-deficient subject.

Hobart MJ, Fernie BA, Würzner R, Oldroyd RG, Harrison RA, Joysey V, Lachmann PJ.

Clin Exp Immunol. 1997 Jun;108(3):500-6.

45.

Herpesvirus saimiri CD59--baculovirus expression and characterisation of complement inhibitory activity.

Bramley JC, Davies A, Lachmann PJ.

Biochem Soc Trans. 1997 May;25(2):354S. No abstract available.

PMID:
9191399
46.

Complement in IgA immune-complex-induced neutrophil activation.

Zhang W, Lucisano YM, Lachmann PJ.

Biochem Soc Trans. 1997 May;25(2):462-6. Review. No abstract available.

PMID:
9191136
48.

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A.

J Clin Invest. 1996 Dec 15;98(12):2819-26.

49.

The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone.

Macanovic M, Sinicropi D, Shak S, Baughman S, Thiru S, Lachmann PJ.

Clin Exp Immunol. 1996 Nov;106(2):243-52.

50.

The in vivo destruction of antigen--a tool for probing and modulating an autoimmune response.

Lachmann PJ.

Clin Exp Immunol. 1996 Nov;106(2):187-9. No abstract available.

Supplemental Content

Loading ...
Support Center